Dynavax Technologies Co. (NASDAQ:DVAX) Sees Large Decline in Short Interest

Dynavax Technologies Co. (NASDAQ:DVAX) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 16,780,000 shares, a drop of 6.3% from the November 30th total of 17,900,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the short-interest ratio is presently 8.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research report on Friday, November 8th.

Institutional Investors Weigh In On Dynavax Technologies

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares in the last quarter. US Bancorp DE raised its stake in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies during the third quarter worth $45,000. Nisa Investment Advisors LLC boosted its stake in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Dynavax Technologies during the 3rd quarter valued at $89,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Down 0.5 %

Shares of NASDAQ DVAX opened at $12.77 on Thursday. The stock has a fifty day moving average price of $12.56 and a 200 day moving average price of $11.56. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $15.01. The company has a market cap of $1.68 billion, a P/E ratio of 98.24 and a beta of 1.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.